NASDAQ:CYCN - Cyclerion Therapeutics Stock Price, Forecast & News

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

Cyclerion Therapeutics Inc (NASDAQ:CYCN) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($1.00) EPS for the quarter. The business earned $1.40 million during the quarter. View Cyclerion Therapeutics' Earnings History.

Cyclerion Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Cyclerion Therapeutics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclerion Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cyclerion Therapeutics.

News headlines about CYCN stock have trended somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cyclerion Therapeutics earned a coverage optimism score of -1.6 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Cyclerion Therapeutics.

Cyclerion Therapeutics saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 776,000 shares, an increase of 6.3% from the December 15th total of 730,200 shares. Based on an average daily trading volume, of 844,100 shares, the days-to-cover ratio is currently 0.9 days. Approximately 3.0% of the company's shares are sold short. View Cyclerion Therapeutics' Current Options Chain.

Some companies that are related to Cyclerion Therapeutics include Lannett (LCI), Kindred Biosciences (KIN), Puma Biotechnology (PBYI), Calithera Biosciences (CALA), Evolus (EOLS), OptiNose (OPTN), Recro Pharma (REPH), Mersana Therapeutics (MRSN), Avid Bioservices (CDMO), MannKind (MNKD), CytomX Therapeutics (CTMX), Cue Biopharma (CUE), Stemline Therapeutics (STML), Satsuma Pharmaceuticals (STSA) and Spectrum Pharmaceuticals (SPPI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Lexicon Pharmaceuticals (LXRX), Solid Biosciences (SLDB), ACADIA Pharmaceuticals (ACAD), Agenus (AGEN), Agile Therapeutics (AGRX), Arrowhead Pharmaceuticals (ARWR), Antares Pharma (ATRS), Axsome Therapeutics (AXSM), Clovis Oncology (CLVS) and Corbus Pharmaceuticals (CRBP).

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CYCN stock can currently be purchased for approximately $3.68.

Cyclerion Therapeutics has a market capitalization of $101.09 million. View Additional Information About Cyclerion Therapeutics.

The official website for Cyclerion Therapeutics is http://www.cyclerion.com/.

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-327-8778 or via email at [email protected]